|
|
Post by rockstarrick on Sept 4, 2018 8:46:34 GMT -5
|
|
|
|
Post by ezrasfund on Sept 4, 2018 9:04:54 GMT -5
Amazing. Perfect partner I would say. ”On the very same day 21 years ago, we enabled the development of treprostinil into a practical treatment thanks to an invention of the late Al Mann – the discrete, ambulatory, programmable, parenteral infusion pump called the MiniMed 407c,” said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. “By marrying our molecule and MiniMed’s device, Remodulin® was born. As we now move into the second generation of United Therapeutics products, we are proud to once again team with Al Mann’s brilliance, this time with his Dreamboat®, Bluhale® and Cricket® devices for inhalation. I believe these revolutionary new inhalation devices will accomplish for Tyvaso® what our recently-approved Implantable System for Remodulin, pending RemUnity™ system and recently-acquired Trevyent® product represent for Remodulin – a further step toward a next generation of treprostinil drug-device systems that enhance options for patients, their families and their prescribers.”  I have followed Martine Rothblatt and United Therapeutics for a long time. Rothblatt is a genius on a par with Al Mann, and like him, started in an unrelated field (satellite radio) before being drawn to health care. She is playing with her own money, and her CV is worth a read. en.wikipedia.org/wiki/Martine_Rothblatt |
|
|
|
Post by uvula on Sept 4, 2018 9:12:47 GMT -5
Particularly nice to see Al Mann being honored.
Does this mean all of the shorts will finally be gone?
If UT has a sales force maybe they can help mnkd spread the word about Afrezza also.
|
|
|
|
Post by awesomo on Sept 4, 2018 9:12:55 GMT -5
Well this is one way to start the short week! Congrats to Mike and the management team for delivering on a heck of a partnership deal in a difficult situation.
|
|
|
|
Post by therealisaching on Sept 4, 2018 9:14:21 GMT -5
Fantastic news, in so many ways, and at the 11th hour makes it even better! Matt and friends haven't posted yet, they're huddling up, perhaps trying to come up with a "trick" play at this point. I am still reeling a bit, though, from Kite have scooped Sla.  Baba,
Sufficient funds to file bk now! Just kidding. Congrats to all.
|
|
|
|
Post by mnkdorbust on Sept 4, 2018 9:24:00 GMT -5
My coffee sure tastes better this morning! Great news and hopefully it will shut the trolls up for a couple of days while they try to decide what to do with their short situation!
|
|
|
|
Post by mnholdem on Sept 4, 2018 9:24:49 GMT -5
Well this is one way to start the short week! Congrats to Mike and the management team for delivering on a heck of a partnership deal in a difficult situation. "Short week" - pardon the pun?  |
|
|
|
Post by awesomo on Sept 4, 2018 9:35:27 GMT -5
Also +1 for Martine Rothblatt being a fellow UCLA Anderson alumni...
|
|
|
|
Post by compound26 on Sept 4, 2018 9:54:02 GMT -5
So glad what I wrote a year ago came out to be true. Mike found a partner who is willing to provide a $50 million upfront fee (we actually got $55 million, if we include the $10 million upfront fee for research collaboration) for a PAH partnership. So happy! Mike is the Man!  mnkd.proboards.com/post/117772 "Mike was talking about a global target population, while you are talking about the US target population. "It’s estimated to impact of 250,000 individuals worldwide". If your number is close to accurate, then Mike's number is very conservative.
And I do not think $860.6 million sales is anywhere underwhelming. And even if Mannkind does 1/10 of it, say $80 million a year, if Mannkind can get $20 million a year of profit out of it, and you give it a 20 time PE, that alone will give you a market cap of $400 million. Remember that our market cap has been hovering around $100 million for a while.
So if we can indeed generate a sale of $800 million a year and if we can get $200 million a year of profit out of it, and you give it a 20 time PE, that alone will give you a market cap of $4 billion, which will translates into a PPS of $40. You are not happy about that?
How about Mike finding some partner who is willing to provide a $50 million upfront fee for a PAH partnership? Mike, let's do it." |
|
|
|
Post by agedhippie on Sept 4, 2018 10:08:30 GMT -5
I am pleasantly surprised (my Calls that I bought in anticipation of the ADA are looking a lot healthier). It makes sense for UTC since this is an area they have sewn up and they don't want the competition. There are some other interesting thoughts - sales from this do not count towards the Deerfield milestone payment. It also alters the dynamic with Deerfield.
|
|
|
|
Post by LongMNKD on Sept 4, 2018 10:15:03 GMT -5
WOW!!!!!!!!!! What a surprise today. I'm so happy i had got shares back at 1.01 now. Best morning EVER!
|
|
|
|
Post by mnholdem on Sept 4, 2018 10:15:05 GMT -5
I'm wondering two things following this announcement:
1. Will TreT development continue? MannKind has yet to announce enrollment for Phase 3 trials. 2. Even though Treprostinil Technoshere (TreT) has yet to be given a marketing name, will it become Remodulin(Technosphere) or Remodulin-TS assuming that TreT uses the same treprostinil API as Remodulin?
I've been wondering why the delay in the Phase 3 trial. Now we know the reason for the delay.
|
|
|
|
Post by kite on Sept 4, 2018 10:18:44 GMT -5
I'm wondering two things following this announcement:
1. Will TreT development continue? MannKind has yet to announce enrollment for Phase 3 trials. 2. Even though Treprostinil Technoshere (TreT) has yet to be given a marketing name, will it become Remodulin(Technosphere) or Remodulin-TS assuming that TreT uses the same treprostinil API as Remodulin?
I've been wondering why the delay in the Phase 3 trial. Now we know the reason for the delay.
Can we imagine the same for the Epi delay? |
|
|
|
Post by lakers on Sept 4, 2018 10:20:20 GMT -5
On 9/30/2016: Ray said "The first is Treprostinil for pulmonary arterial hypertension, PAH. PAH is a sizeable market expected to reach $10 billion by 2020. Treprostinil, a prostacyclin vasodilator is currently available in several formulations. However, these often carry a significant burden. This often leads to poor compliance and poor clinical outcomes. Our Tresprostinil program is in the early technical assessment phase. Preclinical is expected to begin in the second quarter of 2016 followed by clinical trials beginning in first quarter of 2017. We are actively looking for a development partner for this program. Ideally, the partner would be companies that already are active in this space." Competitor is United Therapeutics. The first product to look at is Remodulin, where 7 out of 10 patients on continuous PAH therapy are prescribed this drug. It may be administered as a continuous subcutaneous infusion or continuous intravenous infusion. A drug they market under the name Tyvaso. And guess how Tyvaso is dosed? If you guessed that it is dosed with a United Therapeutics inhaler---BINGO! If you guessed it's treprostinil for PAH, then you get to move to the head of the class. Tyvaso has $450 M/yr run rate. Injected Remodulin has $650M/yr run rate. If the bong-like Tyvaso can sell well, why can't TS PAHale succeed if a reliable partner is found? Tyvaso had to go through the same 5-yr lung and 2-yr pediatric trials as Afrezza will. Somehow, UT marketed it well and made it a success. Mnkd needs to learn from the United Therapeutic Master. ir.unither.com/releasedetail.cfm?ReleaseID=981603 Picture of the huge Tyvaso bong. www.tyvaso.com/hcp/dosage-administration/tyvaso-inhalation-systemRead more: mnkd.proboards.com/thread/6389/inhaled-trespostinil-pah-tyvaso-450m?page=1#ixzz5Q99rmj4G |
|
|
|
Post by lakers on Sept 4, 2018 10:26:46 GMT -5
11/21/2016 by Lakon: Second, United Therapeutics Corporation seems to be a better fit with more in common. Like Mannkind, they were formed by a billionaire trying to solve an unmet medical need, in this case, with a personal connection to the condition PAH, a daughter. There was another background in satellites (spacecraft) and difficulty transitioning to biopharma. With the short-term goal achieved, they are working on the long-term goal of mass producing transplant-able human organs. Interestingly enough from memory, their patent on Treprostinil expires in a few years so they may be interested in a new formulation to extend the runway. MNKD's pipeline includes: MNKD/Treprostinil : UTHR/Tyvaso MNKD/PDE-5 Inhibitor : UTHR/Adcirca MNKD/Patent portfolio : UTHR/Unituxin (GD2-binding monoclonal antibody) MNKD/Tacrolimus : UTHR/Manufactured organs for transplant (Tacrolimus is an anti-rejection drug used after lung transplants...) www.unither.com/pipeline.htmlwww.unither.com/gfx/Pipeline_1010_v1-page-001.jpg (Implantable system for Remodulin and pain-free subq...) www.unither.com/gfx/Pipeline_1010_v1-page-002.jpg (Manufactured organs...) In summary, I'm in favor of many partners, but I can hardly imagine a better fit than UTHR for the future of mankind Read more: mnkd.proboards.com/thread/6389/inhaled-trespostinil-pah-tyvaso-450m?page=2#ixzz5Q9BVFJHm |
|
